Screener
Alamar Biosciences ALMR Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payment of third-party debt issuance costs | (324) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 1,803 | 243 |
| Payment of deferred offering costs | (2,218) | — |
| Net cash provided by financing activities | 55,761 | 243 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (52) | 133 |
| Net increase in cash, cash equivalents and restricted cash | 34,584 | 4,326 |
| Cash, cash equivalents and restricted cash at beginning of period | 34,909 | 31,677 |
| Cash, cash equivalents and restricted cash at end of period | $69,493 | $36,003 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's financing cash flow?
- Alamar Biosciences (ALMR) reported financing cash flow of $55.76M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Alamar Biosciences's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude